LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis

References

• Croia C, Bursi R, Sutera D, et al. One year in review 2019: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(3):347–357.
   PubMed Web of Science ®Google Scholar
• Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–1108.
   PubMed Web of Science ®Google Scholar
• Grassi W, De Angelis R, Lamanna G, et al. The clinical features of rheumatoid arthritis. Eur J Radiol. 1998;27(Suppl 1):S18–24.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Chronic rheumatic conditions [Internet]. 2019 [cited 2019 Aug 8]. Available from: https://www.who.int/chp/topics/rheumatic/en/
   Google Scholar
• Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother. 2004;5(3):581–594.
   PubMed Web of Science ®Google Scholar
• Rein P, Mueller RB. Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatol Ther. 2017;4(2):247–261.
   PubMed Web of Science ®Google Scholar
• Chinese Rheumatology Association. 2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis. Zhonghua Nei Ke Za Zhi. 2018;57(4):242–251. Chinese.
   PubMedGoogle Scholar
• Kameda H, Fujii T, Nakajima A, et al. Japan college of rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol. 2019;29(1):31–40.
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology. Updated guideline for the management of rheumatoid arthritis 2018 [Internet]. 2018 [cited 2019 Aug 8]. Available from: https://www.rheumatology.org/Portals/0/Files/Rheumatoid-Arthritis-Guideline-Project-Plan.pdf
   Google Scholar
• Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977.
   PubMed Web of Science ®Google Scholar
• Food & Drug Administration. Information on tumor necrosis factor (TNF) blockers (marketed as remicade, enbrel, humira, cimzia, and simponi) [Internet]. 2015 [cited 2019 Aug 8]. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-tumor-necrosis-factor-tnf-blockers-marketed-remicade-enbrel-humira-cimzia-and-simponi
   Google Scholar
• Hassett B, Singh E, Mahgoub E, et al. Manufacturing history of etanercept (Enbrel®): consistency of product quality through major process revisions. MAbs. 2018;10(1):159–165.
   PubMed Web of Science ®Google Scholar
• Son JH, Cha SW. Anti-TNF-alpha therapy for ankylosing spondylitis. Clin Orthop Surg. 2010;2(1):28–33.
   PubMedGoogle Scholar
• Miyasaka N, Takeuchi T, Eguchi K. Guidelines for the proper use of etanercept in Japan. Mod Rheumatol. 2006;16(2):63–67.
   PubMedGoogle Scholar
• Manova M, Savova A, Vasileva M, et al. Comparative price analysis of biological products for treatment of rheumatoid arthritis. Front Pharmacol. 2018;9:1070.
   PubMed Web of Science ®Google Scholar
• Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3.
   PubMedGoogle Scholar
• Schulze-Koops H, Skapenko A. Biosimilars in rheumatology: a review of the evidence and their place in the treatment algorithm. Rheumatology (Oxford). 2017;56(Suppl4):iv30–iv48.
   PubMed Web of Science ®Google Scholar
• Remuzat C, Dorey J, Cristeau O, et al. Key drivers for market penetration of biosimilars in Europe. J Mark Access Health Policy. 2017;5(1):1272308.
   PubMedGoogle Scholar
• Declerck P, Danesi R, Petersel D, et al. The language of biosimilars: clarification, definitions, and regulatory aspects. Drugs. 2017;77(6):671–677.
   PubMed Web of Science ®Google Scholar
• Kuribayashi R, Sawanobori K. Current Japanese regulatory systems for generics and biosimilars. J Pharm Sci. 2018;107(3):785–787.
   PubMed Web of Science ®Google Scholar
• Mysler E, Pineda C, Horiuchi T, et al. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatol Int. 2016;36(5):613–625.
   PubMed Web of Science ®Google Scholar
• Tesser JR, Furst DE, Jacobs I. Biosimilars and the extrapolation of indications for inflammatory conditions. Biologics. 2017;11:5–11.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Sorensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76(8):1426–1431.
   PubMed Web of Science ®Google Scholar
• Goll GL, Jorgensen KK, Sexton J, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. J Intern Med. 2019;285(6):653–669.
   PubMed Web of Science ®Google Scholar
• Jaworski J, Matucci-Cerinic M, Schulze-Koops H, et al. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. Arthritis Res Ther. 2019;21(1):130.
   PubMed Web of Science ®Google Scholar
• Park W, Suh CH, Shim SC, et al. Efficacy and safety of switching from innovator rituximab to biosimilar CT-P10 compared with continued treatment with CT-P10: results of a 56-week open-label study in patients with rheumatoid arthritis. BioDrugs. 2017;31(4):369–377.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Choe JY, Prodanovic N, et al. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. Ann Rheum Dis. 2018;77(2):234–240.
   PubMed Web of Science ®Google Scholar
• Pelechas E, Drosos AA. Etanercept biosimilar SB-4. Expert Opin Biol Ther. 2019;19(3):173–179.
   PubMed Web of Science ®Google Scholar
• Pelechas E, Voulgari PV, Drosos AA. ABP 501 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2018;18(3):317–322.
   PubMed Web of Science ®Google Scholar
• Kaltsonoudis E, Pelechas E, Voulgari PV, et al. Maintained clinical remission in ankylosing spondylitis patients switched from reference infliximab to its biosimilar: an 18-month comparative open-label study. J Clin Med. 2019;8(7):pii:E956.
   PubMed Web of Science ®Google Scholar
• Aladul MI, Fitzpatrick RW, Chapman SR. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: results of a budget impact analysis. Res Social Adm Pharm. 2019;15(3):310–317.
   PubMed Web of Science ®Google Scholar
• Quintiles IMS. The impact of biosimilar competition in Europe [Internet]. 2017 [cited 2019 Aug 8]. Available from: https://www.medicinesforeurope.com/wp-content/uploads/2017/05/IMS-Biosimilar-2017_V9.pdf
   Google Scholar
• LaMerie. Blockbuster biologics 2018: sales of recombinant therapeutic antibodies & proteins [Internet]. 2018. [cited 2019 Aug 8]. Available from: https://lamerie.com/report/blockbuster-biologics-2018-sales-of-recombinant-therapeutic-antibodies-proteins/
   Google Scholar
• Cohen S, Kay J. Biosimilars: implications for rheumatoid arthritis therapy. Curr Opin Rheumatol. 2017;29(3):260–268.
   PubMed Web of Science ®Google Scholar
• Kaida-Yip F, Deshpande K, Saran T, et al. Biosimilars: review of current applications, obstacles, and their future in medicine. World J Clin Cases. 2018;6(8):161–166.
   PubMed Web of Science ®Google Scholar
• Biogen. 2018 annual report [Internet]. 2019 [cited 2019 Aug 8]. Available from: https://biogen.gcs-web.com/static-files/30ea6b55-6a57-48ae-840d-96ac58ddf031
   Google Scholar
• Kyono H, Haraguchi K, Kojima S, et al. Quality characteristics and nonclinical/clinical profiles of Etanercept BS SC [MA]. Folia Pharmacol Jpn. 2018;151(6):261–272. Japanese.
   PubMedGoogle Scholar
• Lee H, Chung H, Lee S, et al. LBEC0101, A proposed etanercept biosimilar: pharmacokinetics, immunogenicity, and tolerability profiles compared with a reference biologic product in healthy male subjects. BioDrugs. 2017;31(4):349–355.
   PubMed Web of Science ®Google Scholar
• Matsuno H, Tomomitsu M, Hagino A, et al. Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate. Ann Rheum Dis. 2018;77(4):488–494.
   PubMed Web of Science ®Google Scholar
• Mochida Pharmaceutical Co. L. Mochida obtains marketing approval for etanercept biosimilar in Japan [Internet]. 2018 [cited 2019 Aug 8]. Available from: http://www.mochida.co.jp/english/news/docs/2018/180119_etanerceptBS.pdf
   Google Scholar
• Center for Biosimilars. Eye on pharma: LG chem’s etanercept biosimilar gains Korean approval [Internet]. 2019 [cited 2019 July 9]. Available from: https://www.centerforbiosimilars.com/news/eye-on-pharma-lg-chems-etanercept-biosimilar-gains-korean-approval
   Google Scholar
• Park MC, Matsuno H, Kim J, et al. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study. Arthritis Res Ther. 2019;21(1):122.
   PubMed Web of Science ®Google Scholar
• Emery P, Vencovsky J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76(1):51–57.
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic M, Allanore Y, Kavanaugh A, et al. Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. RMD Open. 2018;4:e000757.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Thaci D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176(4):928–938.
   PubMed Web of Science ®Google Scholar
• Girolomoni G, Feldman SR, Emery P, et al. Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study. Br J Dermatol. 2018;178(3):e215–e216.
   PubMed Web of Science ®Google Scholar
• Jaber A, Bozzato GB, Vedrine L, et al. A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis. BMC Neurol. 2008;8:38.
   PubMed Web of Science ®Google Scholar
• Glenski S, Conner J. 29 gauge needles improve patient satisfaction over 27 gauge needles for daily glatiramer acetate injections. Drug Healthc Patient Saf. 2009;1:81–86.
   PubMedGoogle Scholar
• Arendt-Nielsen L, Egekvist H, Bjerring P. Pain following controlled cutaneous insertion of needles with different diameters. Somatosens Mot Res. 2006;23(1–2):37–43.
   PubMed Web of Science ®Google Scholar
• Siegmund T, Blankenfeld H, Schumm-Draeger PM. Comparison of usability and patient preference for insulin pen needles produced with different production techniques: “thin-wall” needles compared to “regular-wall” needles: an open-label study. Diabetes Technol Ther. 2009;11(8):523–528.
   PubMed Web of Science ®Google Scholar